# Mirati Therapeutics Inc. clinical trials: 51 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials with Mirati Therapeutics Inc. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Mirati Therapeutics Inc.: 51 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/mirati-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 23, 2026 | NCT07723118 | A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese... | Mirati Therapeutics Inc. | Phase 1 | Completed | Healthy Participants | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723118) |
| February 17, 2026 | NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | Mirati Therapeutics Inc. | Phase 2 | Recruiting | Solid Tumors | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415031) |
| March 13, 2025 | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously... | Mirati Therapeutics Inc. | Phase 3 | Recruiting | Carcinoma, Non-Small-Cell Lung | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06875310) |
| January 30, 2025 | NCT06801418 | Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets | Mirati Therapeutics Inc. | Phase 1 | Completed | Healthy Volunteers | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06801418) |
| June 29, 2023 | NCT05924152 | A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib | Mirati Therapeutics Inc. | Phase 1 | Completed | Healthy Adults | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05924152) |
| May 22, 2023 | NCT05868356 | A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib | Mirati Therapeutics Inc. | Phase 1 | Completed | Healthy Adults | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05868356) |
| May 10, 2023 | NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Mirati Therapeutics Inc. | Phase 2 | Active not recruiting | Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05853575) |
| May 3, 2023 | NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation... | Mirati Therapeutics Inc. | Phase 1 | Terminated | Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05840510) |
| February 21, 2023 | NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Mirati Therapeutics Inc. | Phase 1 | Terminated | Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05737706) |
| November 8, 2022 | NCT05609578 | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Mirati Therapeutics Inc. | Phase 2 | Active not recruiting | Advanced NSCLC, Metastatic Lung Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05609578) |
| October 13, 2022 | NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Mirati Therapeutics Inc. | Phase 1 | Terminated | Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05578092) |
| February 24, 2022 | NCT05255276 | PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. | Mirati Therapeutics Inc. | Phase 1 | Completed | Healthy Adults | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05255276) |
| January 5, 2022 | NCT05178888 | Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) | Mirati Therapeutics Inc. | Phase 1 | Completed | Advanced Solid Tumor | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05178888) |
| July 23, 2021 | NCT04975256 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Mirati Therapeutics Inc. | Phase 1 | Terminated | Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung, Malignant Neoplastic... | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04975256) |
| June 22, 2021 | NCT04935112 | A Study to Explore the Effect of Acid-reducing Agents | Mirati Therapeutics Inc. | Phase 1 | Completed | Healthy Adults | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04935112) |
| May 14, 2021 | NCT04887870 | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | Mirati Therapeutics Inc. | Phase 2/3 | Completed | Advanced or Metastatic Solid Malignancies | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04887870) |
| May 14, 2021 | NCT04887194 | PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates | Mirati Therapeutics Inc. | Phase 1 | Completed | Advanced Solid Tumor | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04887194) |
| March 16, 2021 | NCT04800614 | A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib | Mirati Therapeutics Inc. | Phase 1 | Completed | Healthy Adults | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04800614) |
| March 11, 2021 | NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Mirati Therapeutics Inc. | Phase 3 | Active not recruiting | Advanced Colorectal Cancer, Metastatic Colorectal Cancer | 461 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04793958) |
| February 26, 2021 | NCT04772612 | A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib | Mirati Therapeutics Inc. | Phase 1 | Completed | Hepatic Impairment | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04772612) |
| December 28, 2020 | NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | Mirati Therapeutics Inc. | Phase 3 | Active not recruiting | Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | 453 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04685135) |
| November 3, 2020 | NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients... | Mirati Therapeutics Inc. | Phase 2/3 | Recruiting | Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04613596) |
| August 19, 2020 | NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | Mirati Therapeutics Inc. | Phase 1 | Completed | Clear-Cell Renal Cell Carcinoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04518046) |
| April 1, 2020 | NCT04330664 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Mirati Therapeutics Inc. | Phase 1 | Completed | Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04330664) |
| April 8, 2019 | NCT03906071 | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | Mirati Therapeutics Inc. | Phase 3 | Terminated | Metastatic Non-Squamous Non-Small Cell Lung Cancer | 577 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03906071) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 25 |
| Phase 1/2 | 5 |
| Phase 2 | 14 |
| Phase 2/3 | 2 |
| Phase 3 | 4 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 29 |
| Terminated | 14 |
| Active not recruiting | 5 |
| Recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 15 |
| Neoplasms | 9 |
| Neoplasm Metastasis | 8 |
| Colonic Neoplasms | 6 |
| Myelodysplastic Syndromes | 6 |
| Colorectal Neoplasms | 5 |
| Pancreatic Neoplasms | 4 |
| Lung Neoplasms | 4 |
| Leukemia | 3 |
| Carcinoma, Renal Cell | 3 |
| Leukemia, Myeloid, Acute | 3 |
| Lymphoma, Non-Hodgkin | 2 |
| Recurrence | 2 |
| Carcinoma, Transitional Cell | 2 |
| Hodgkin Disease | 2 |
| Prostatic Neoplasms | 2 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Leukemia, Lymphoid | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Lymphoma | 1 |
| Rubinstein-Taybi Syndrome | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Glass manufacturers in the United States](https://specstream.ai/data/businesses/glass-manufacturers/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Shipping collection companies in the United States](https://specstream.ai/data/businesses/shipping-collection-companies/united-states)
- [IT consultants in the United States](https://specstream.ai/data/businesses/it-consultants/united-states)
- [Comfort food restaurants in the United States](https://specstream.ai/data/businesses/comfort-food-restaurants/united-states)
- [Truck and industrial vehicle companies in the United States](https://specstream.ai/data/businesses/truck-and-industrial-vehicle-companies/united-states)
